The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction
- PMID: 34864931
- DOI: 10.1093/eurheartj/ehab715
The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction
Comment on
-
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. N Engl J Med. 2021. PMID: 34449189 Clinical Trial.
Similar articles
-
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.Eur J Heart Fail. 2019 Oct;21(10):1279-1287. doi: 10.1002/ejhf.1596. Epub 2019 Sep 16. Eur J Heart Fail. 2019. PMID: 31523904
-
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.Eur J Heart Fail. 2020 Dec;22(12):2383-2392. doi: 10.1002/ejhf.2064. Eur J Heart Fail. 2020. PMID: 33251670 Clinical Trial.
-
A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial'.Eur J Heart Fail. 2021 May;23(5):841. doi: 10.1002/ejhf.2091. Epub 2021 Feb 4. Eur J Heart Fail. 2021. PMID: 33377246 No abstract available.
-
Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?J Diabetes. 2021 Jul;13(7):596-600. doi: 10.1111/1753-0407.13182. Epub 2021 Apr 21. J Diabetes. 2021. PMID: 33792199
-
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.JACC Heart Fail. 2018 Aug;6(8):633-639. doi: 10.1016/j.jchf.2018.01.009. Epub 2018 Mar 7. JACC Heart Fail. 2018. PMID: 29525327 Review.
Cited by
-
Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update.Cardiovasc Drugs Ther. 2023 Aug;37(4):815-832. doi: 10.1007/s10557-021-07306-8. Epub 2022 Jan 31. Cardiovasc Drugs Ther. 2023. PMID: 35098432 Free PMC article. Review.
-
Cardiac rehabilitation for heart failure: 'Cinderella' or evidence-based pillar of care?Eur Heart J. 2023 May 1;44(17):1511-1518. doi: 10.1093/eurheartj/ehad118. Eur Heart J. 2023. PMID: 36905176 Free PMC article. Review.
-
Empagliflozin-A New Chance for Patients with Chronic Heart Failure.Pharmaceuticals (Basel). 2021 Dec 30;15(1):47. doi: 10.3390/ph15010047. Pharmaceuticals (Basel). 2021. PMID: 35056104 Free PMC article. Review.
-
Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus.Int J Mol Sci. 2022 Mar 25;23(7):3587. doi: 10.3390/ijms23073587. Int J Mol Sci. 2022. PMID: 35408946 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical